These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 31844135)
1. Quantitative background parenchymal enhancement to predict recurrence after neoadjuvant chemotherapy for breast cancer. Moliere S; Oddou I; Noblet V; Veillon F; Mathelin C Sci Rep; 2019 Dec; 9(1):19185. PubMed ID: 31844135 [TBL] [Abstract][Full Text] [Related]
2. Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. Choi JS; Ko ES; Ko EY; Han BK; Nam SJ Medicine (Baltimore); 2016 Mar; 95(9):e3000. PubMed ID: 26945421 [TBL] [Abstract][Full Text] [Related]
3. Role of dynamic contrast-enhanced MRI in evaluating the association between contralateral parenchymal enhancement and survival outcome in ER-positive, HER2-negative, node-negative invasive breast cancer. Shin GW; Zhang Y; Kim MJ; Su MY; Kim EK; Moon HJ; Yoon JH; Park VY J Magn Reson Imaging; 2018 Dec; 48(6):1678-1689. PubMed ID: 29734483 [TBL] [Abstract][Full Text] [Related]
4. Background parenchymal enhancement on breast MRI: association with recurrence-free survival in patients with newly diagnosed invasive breast cancer. Lim Y; Ko ES; Han BK; Ko EY; Choi JS; Lee JE; Lee SK Breast Cancer Res Treat; 2017 Jun; 163(3):573-586. PubMed ID: 28349273 [TBL] [Abstract][Full Text] [Related]
5. Relationship between background parenchymal enhancement on breast MRI and pathological tumor response in breast cancer patients receiving neoadjuvant chemotherapy. Oh SJ; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH Br J Radiol; 2018 Jul; 91(1088):20170550. PubMed ID: 29848015 [TBL] [Abstract][Full Text] [Related]
6. Association between contralateral background parenchymal enhancement on MRI and outcome in patients with unilateral invasive breast cancer receiving neoadjuvant chemotherapy. Rella R; Bufi E; Belli P; Scrofani AR; Petta F; Borghetti A; Marazzi F; Valentini V; Manfredi R Diagn Interv Imaging; 2022 Oct; 103(10):486-494. PubMed ID: 35585020 [TBL] [Abstract][Full Text] [Related]
7. Association between background parenchymal enhancement and tumor response in patients with breast cancer receiving neoadjuvant chemotherapy. Rella R; Bufi E; Belli P; Petta F; Serra T; Masiello V; Scrofani AR; Barone R; Orlandi A; Valentini V; Manfredi R Diagn Interv Imaging; 2020 Oct; 101(10):649-655. PubMed ID: 32654985 [TBL] [Abstract][Full Text] [Related]
8. Decreased background parenchymal enhancement of the contralateral breast after two cycles of neoadjuvant chemotherapy is associated with tumor response in HER2-positive breast cancer. You C; Gu Y; Peng W; Li J; Shen X; Liu G; Peng W Acta Radiol; 2018 Jul; 59(7):806-812. PubMed ID: 29065702 [TBL] [Abstract][Full Text] [Related]
9. Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI. Chen JH; Yu H; Lin M; Mehta RS; Su MY Magn Reson Imaging; 2013 Nov; 31(9):1465-71. PubMed ID: 23992630 [TBL] [Abstract][Full Text] [Related]
10. Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response. Preibsch H; Wanner L; Bahrs SD; Wietek BM; Siegmann-Luz KC; Oberlecher E; Hahn M; Staebler A; Nikolaou K; Wiesinger B Eur Radiol; 2016 Jun; 26(6):1590-6. PubMed ID: 26382845 [TBL] [Abstract][Full Text] [Related]
11. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response. Onishi N; Li W; Newitt DC; Harnish RJ; Strand F; Nguyen AA; Arasu VA; Gibbs J; Jones EF; Wilmes LJ; Kornak J; Joe BN; Price ER; Ojeda-Fournier H; Eghtedari M; Zamora KW; Woodard S; Umphrey HR; Nelson MT; Church AL; Bolan PJ; Kuritza T; Ward K; Morley K; Wolverton D; Fountain K; Lopez Paniagua D; Hardesty L; Brandt KR; McDonald ES; Rosen M; Kontos D; Abe H; Sheth D; Crane E; Dillis C; Sheth P; Hovanessian-Larsen L; Bang DH; Porter B; Oh KY; Jafarian N; Tudorica LA; Niell B; Drukteinis J; Newell MS; Giurescu ME; Berman E; Lehman CD; Partridge SC; Fitzpatrick KA; Borders MH; Yang WT; Dogan B; Goudreau SH; Chenevert T; Yau C; DeMichele A; Berry DA; Esserman LJ; Hylton NM Radiology; 2021 Nov; 301(2):295-308. PubMed ID: 34427465 [TBL] [Abstract][Full Text] [Related]
12. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR). Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493 [TBL] [Abstract][Full Text] [Related]
13. Predictive value of background parenchymal enhancement on breast magnetic resonance imaging for pathological tumor response to neoadjuvant chemotherapy in breast cancers: a systematic review. Li X; Yan F Cancer Imaging; 2024 Mar; 24(1):35. PubMed ID: 38462607 [TBL] [Abstract][Full Text] [Related]
14. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer. Loo CE; Rigter LS; Pengel KE; Wesseling J; Rodenhuis S; Peeters MJ; Sikorska K; Gilhuijs KG Breast Cancer Res; 2016 Aug; 18(1):82. PubMed ID: 27495815 [TBL] [Abstract][Full Text] [Related]
15. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy. Choi BB; Kim SH Acta Radiol; 2015 Jul; 56(7):790-7. PubMed ID: 24951616 [TBL] [Abstract][Full Text] [Related]
16. Ring Enhancement in Non-Neoplastic Breast Tissue on MRI During Neoadjuvant Chemotherapy for Breast Cancer: Incidence and Clinical Implications. Oh J; Han BK; Ko EY; Ko ES; Choi JS; Kim H; Park YH; Kim JY Acad Radiol; 2023 Dec; 30(12):2931-2939. PubMed ID: 37045651 [TBL] [Abstract][Full Text] [Related]
17. Amount of fibroglandular tissue FGT and background parenchymal enhancement BPE in relation to breast cancer risk and false positives in a breast MRI screening program : A retrospective cohort study. Vreemann S; Dalmis MU; Bult P; Karssemeijer N; Broeders MJM; Gubern-Mérida A; Mann RM Eur Radiol; 2019 Sep; 29(9):4678-4690. PubMed ID: 30796568 [TBL] [Abstract][Full Text] [Related]
18. Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging. Iotti V; Ravaioli S; Vacondio R; Coriani C; Caffarri S; Sghedoni R; Nitrosi A; Ragazzi M; Gasparini E; Masini C; Bisagni G; Falco G; Ferrari G; Braglia L; Del Prato A; Malavolti I; Ginocchi V; Pattacini P Breast Cancer Res; 2017 Sep; 19(1):106. PubMed ID: 28893303 [TBL] [Abstract][Full Text] [Related]
19. Dynamic contrast-enhanced breast magnetic resonance imaging for the prediction of early and late recurrences in breast cancer. Choi EJ; Choi H; Choi SA; Youk JH Medicine (Baltimore); 2016 Nov; 95(48):e5330. PubMed ID: 27902592 [TBL] [Abstract][Full Text] [Related]
20. Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy. Asaoka M; Narui K; Suganuma N; Chishima T; Yamada A; Sugae S; Kawai S; Uenaka N; Teraoka S; Miyahara K; Kawate T; Sato E; Nagao T; Matsubara Y; Gandhi S; Takabe K; Ishikawa T Eur J Surg Oncol; 2019 Dec; 45(12):2289-2294. PubMed ID: 31787153 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]